Prolonged Hemocoagulase Agkistrodon Halys Pallas Administration Induces Hypofibrinogenemia in Patients with Hematological Disorders: A Clinical Analysis of 11 Patients
- 48 Downloads
Hemocoagulase Agkistrodon Halys Pallas, a well-established hemostatic agent used in China, has widespread applications in various conditions of bleeding and hemorrhages. Although it presents a low risk of vascular thrombosis, the agent can be easily tolerated and does not show any harmful effects, except allergy. However, long-term use of hemocoagulase may induce hypofibrinogenemia in some patients. Herein, we report 11 patients of prolonged administration of hemocoagulase Agkistrodon, with particular attention to the dynamic changes in their coagulation functions. A marked decline in the level of fibrinogen was observed in patients suffering from hematological disorders, following an extended exposure to hemocoagulase. Nevertheless, the low fibrinogen levels increased after withdrawal of the agent. Since the D-dimer level did not show any significant increase, hemocoagulase inducing lower fibrinogen may be considered to be a process of primary fibrinolysis. In conclusion, we suggested that hemocoagulase must be cautiously used in patients with hematological disorders, because of the potential risk of fibrinolysis; and the coagulation functions should be carefully evaluated during the administration of hemocoagulase.
KeywordsBatroxobin Anemia Aplastic Fibrinolysis Afibrinogenemia Myelodysplastic syndromes
Wu Dijiong contributed to the conception of the study. Xu Linglong contributed to data collection, performed the data analyses and wrote the manuscript.
- 6.Hui-Min L, Chang-Ling LI, Dong JC, Zhang CL (2008) Hemostatic effect of hemocoagulase agkistrodon and its mechanism. J Exp Hematol 16(4):883–885Google Scholar
- 7.Wei JM, Zhu MW, Zhang ZT, Jia ZG, Xiao-Dong HE, Wan YL et al (2007) The effects of hemocoagulase agkistrodon on its hemostatic and hemoagglutinant function, on abdominal incision and safety in surgical patients, a multicenter clinical study. Chin J New Drugs 16(14):1126–1129Google Scholar
- 9.Jr TF, Toh CH, Hoots WK et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327Google Scholar
- 14.Xu YY, Li BL, Jin YL, Wang ZX, Song XR, Ni J (2014) Serious anaphylactic shock induced by hemocoagulase agkistrodon during anesthesia in a 5-year-old child. Int J Clin Exp Med 8(3):4727–4730Google Scholar
- 17.Xu G, Liu X, Zhu W, Yin Q, Zhang R, Fan X (2007) Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis Int J Haemost Thrombosis 18(2):193–197. doi: 10.1097/MBC.0b013e328040c0f2 CrossRefGoogle Scholar